Wednesday | 15 October, 2008
Mesoblast's long-term protection
Mesoblast awarded extended patent for MPC stem cells
Additional Resources
Newsletter Subscription
Mesoblast [ASX: MSB] has been granted a US patent through to 2019 for its Mesenchymal Precursor Cells [MPC], proprietary adult stem cells developed by Mesoblast and its sister company Angioblast Systems.
The patent ensures only Mesoblast and Angioblast can commercialise MPCs in the US.
MPCs were first identified in Australia, at the Hanson Institute in Adelaide. They are capable of repairing and regenerating a host of tissue types, including bone, cartilage, fat, blood vessels and heart muscle.
More about MPC
Australian Life Scientist Member Login
Fujitsu PC targets Today's Young Adults with the release of the L series 2008-10-14 12:40:00+10
Sound Alliance Group expands with acquisition of Mess+Noise 2008-10-14 08:48:00+10
IOGEAR Gears Up in Australia 2008-10-09 20:18:00+10
ACRONIS NAMES INDUSTRY VETERAN JASON DONAHUE AS CEO 2008-10-09 09:37:00+10
Multimedia Technology signs exclusive National distribution agreement with Freecom 2008-10-07 14:30:00+10
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector. ALS is available free of charge to qualified persons working in the life sciences - register now for your free subscription.
